This result confirms previous findings showing that the transgenic tau-VLW mouse model of tauopathy [38,39] is characterized by an ageing-dependent brain glucose hypometabolism, starting at 11 months of age and becoming more evident in older animals and further correlating with histopathological markers of neurodegeneration in the brain areas overexpressing tau protein [37]. This evidence concerns the gene MAPT and tauopathy.